Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
Matthias Pinter(Medical University of Vienna), Markus Peck‐Radosavljevic(Klinikum Klagenfurt), Maximilian Schöniger–Hekele(Arbeitsgemeinschaft für Klinische Ernährung), Wolfgang Sieghart(Atitus Educação), Cyril Muller(Arbeitsgemeinschaft für Klinische Ernährung), Birgit Grünberger(Fachhochschule Wiener Neustadt), Robert Königsberg(Kaiser-Franz-Josef-Spital), A Maieron(Universitätsklinikum St. Pölten), R. Buder(Convent Hospital of the Brothers of Saint John of God), J. Matejka(University of Graz), I Graziadei(Innsbruck Medical University), W. Vogel(Innsbruck Medical University), Gabriela Kornek(Medical University of Vienna), Florian Hucke(Klinikum Klagenfurt), A Weissmann(Wilhelminen Hospital), Rudolf Stauber(Medical University of Graz)
Cited by 73
Related Papers
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Proton transfer reaction mass spectrometry: on-line trace gas analysis at the ppb level
|International Journal of Mass Spectrometry and Ion Processes|1995|765
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484